Rigel Pharmaceuticals sees Q3 Tavalisse sales up 15% from Q2 to $11.7M
Rigel Pharmaceuticals provided a business update. Preliminary estimates indicate that Tavalisse net product sales continued to achieve double digit quarter over quarter growth, increasing 15% to $11.7M from $10.2M in Q2. Rigel completed a Phase 1 clinical trial of R835, an interleukin-1 receptor-associated kinase 1/4 inhibitor. In addition to positive tolerability and pharmacokinetic data, R835 showed consistent inhibition of cytokine production in an LPS challenge which was designed to gauge the molecule's impact on inflammatory stimulation. Rigel announced its new receptor-interacting protein kinase inhibitor program. The lead molecule, R552, has initiated a Phase 1 clinical trial. RIP1 is believed to be a key driver of necroptosis.